The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > ACADEMIA
ACADEMIA
- Japan Cancer Association to Release Statement on Health Spending at Sept. Meeting
August 24, 2018
- Only 30% of Patients Took Thyroid Tests before Receiving Dementia Meds: Survey
July 25, 2018
- Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
- Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
July 11, 2018
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study
June 27, 2018
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
- Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- Nephrology Society to Issue New CKD Guidelines; Recommends Less-Strict Blood Pressure Management Target
June 4, 2018
- AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist
May 28, 2018
- Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass
May 21, 2018
- Dupixent Used Generally as Adjunctive Therapy to Existing Treatments for Atopic Dermatitis: Dermatologist
May 10, 2018
- 55 Anticancer Meds Available Overseas Unapproved in Japan, 3 Meds Costing over 10 Million Yen Monthly: NCC
May 2, 2018
- New Guidelines Recommend LAMA as First-Line Bronchodilator for COPD: Respiratory Society
April 24, 2018
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
- Expert Cautions against Hasty Discussions on Cost Effective Assessments
April 20, 2018
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President
April 19, 2018
- Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…